Wedbush Predicts Biogen's Q1 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB - Free Report) - Wedbush cut their Q1 2025 earnings per share (EPS) estimates for shares of Biogen in a research note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings per share of $3.51 for the quarter, down from their previous estimate of $3.82. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen's Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $17.02 EPS and FY2027 earnings at $17.83 EPS.

A number of other brokerages also recently weighed in on BIIB. HC Wainwright cut their price target on shares of Biogen from $300.00 to $241.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Citigroup decreased their price target on shares of Biogen from $160.00 to $145.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Royal Bank of Canada raised their price objective on Biogen from $221.00 to $225.00 and gave the stock an "outperform" rating in a research note on Tuesday. StockNews.com downgraded Biogen from a "strong-buy" rating to a "buy" rating in a report on Saturday, December 28th. Finally, William Blair reiterated an "outperform" rating on shares of Biogen in a report on Monday, January 13th. Eighteen investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $213.15.

Biogen Trading Up 2.0 %

Shares of Biogen stock traded up $2.34 during trading on Thursday, reaching $118.83. 272,454 shares of the company were exchanged, compared to its average volume of 1,351,416. Biogen has a twelve month low of $110.04 and a twelve month high of $238.00. The business has a 50-day moving average price of $133.95 and a 200-day moving average price of $150.71. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $17.39 billion, a price-to-earnings ratio of 10.61, a P/E/G ratio of 1.51 and a beta of 0.06.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating analysts' consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Institutional Trading of Biogen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BIIB. Larson Financial Group LLC lifted its position in Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 141 shares in the last quarter. Lee Danner & Bass Inc. bought a new stake in Biogen during the fourth quarter worth $25,000. Opal Wealth Advisors LLC purchased a new stake in Biogen in the 1st quarter valued at $26,000. Colonial Trust Co SC boosted its holdings in Biogen by 9,300.0% during the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 186 shares during the last quarter. Finally, OFI Invest Asset Management bought a new stake in shares of Biogen in the 4th quarter worth $32,000. 87.93% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now owns 11,318 shares in the company, valued at $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.